Second-line therapy for metastatic colorectal cancer
Mené sur 1 072 patients atteints d'un cancer colorectal métastatique, cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout de ramucirumab à une chimiothérapie FOLFIRI en traitement de deuxième ligne
The CALGB/SWOG 80405 trial explored which biological (antibodies to VEGF or EGFR) to partner with first-line chemotherapy in patients with RAS wild-type metastatic colorectal cancer. Although the debate of which biological to combine with first-line therapy continues, the reported median overall survival is well beyond 24 months, which is due partly to the treatment options available beyond first-line therapy.1 The ability of clinicians to make evidence-based decisions on the timings and combinations of therapies, therefore, is becoming increasingly important.
The Lancet Oncology , commentaire, 2014